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CB1 Antagonism Exerts Speciﬁc Molecular Effects on
Visceral and Subcutaneous Fat and Reverses Liver
Steatosis in Diet-Induced Obese Mice
Tony Jourdan, Louiza Djaouti, Laurent Demizieux, Joseph Gresti, Bruno Verge `s, and Pascal Degrace
OBJECTIVE—The beneﬁcial effects of the inactivation of endo-
cannabinoid system (ECS) by administration of antagonists of
the cannabinoid receptor (CB) 1 on several pathological features
associated with obesity is well demonstrated, but the relative
contribution of central versus peripheral mechanisms is unclear.
We examined the impact of CB1 antagonism on liver and
adipose tissue lipid metabolism in a mouse model of diet-induced
obesity.
RESEARCH DESIGN AND METHODS—Mice were fed either
with a standard diet or a high-sucrose high-fat (HSHF) diet for
19 weeks and then treated with the CB1-speciﬁc antagonist
SR141716 (10 mg  kg
1  day
1) for 6 weeks.
RESULTS—Treatment with SR141716 reduced fat mass, insulin
levels, and liver triglycerides primarily increased by HSHF feed-
ing. Serum adiponectin levels were restored after being reduced
in HSHF mice. Gene expression of scavenger receptor class B
type I and hepatic lipase was induced by CB1 blockade and
associated with an increase in HDL-cholesteryl ether uptake.
Concomitantly, the expression of CB1, which was strongly
increased in the liver and adipose tissue of HSHF mice, was
totally normalized by the treatment. Interestingly, in visceral but
not subcutaneous fat, genes involved in transport, synthesis,
oxidation, and release of fatty acids were upregulated by HSHF
feeding, while this effect was counteracted by CB1 antagonism.
CONCLUSIONS—A reduction in the CB1-mediated ECS activity
in visceral fat is associated with a normalization of adipocyte
metabolism, which may be a determining factor in the reversion
of liver steatosis induced by treatment with SR141716. Diabetes
59:926–934, 2010
O
besity results from an imbalance between en-
ergy intake and expenditure and is character-
ized by increased body weight and abnormal
development of adipose tissue with excessive
fat storage (1). Recently, evidence has accumulated for the
overactivity of the endocannabinoid system (ECS) during
conditions of unbalanced energy homeostasis (2). The
ECS consists of the cannabinoid receptors (CBs), their
endogenous ligands (the endocannabinoids), and the en-
zyme proteins catalyzing the endocannabinoid formation
and degradation (3). Activation of central CB1 receptors
clearly promotes food intake and weight gain (4–6).
Accordingly, pharmacological antagonism of CB1 has
been shown to improve several pathological features
associated with obesity, including overweight, hyperinsu-
linemia, insulin resistance, hyperglycemia, and dyslipide-
mia in obese rodents (7–9) and humans (10,11).
Even if the reduction in food intake induced by central
CB1 blockade may be the main initial cause of body weight
loss and associated beneﬁcial effects, several data col-
lected from animal and human studies indicate that pe-
ripheral CB1 may also directly control lipid metabolism
(12–14). Thus, an activation of ECS has been recently
reported in peripheral tissues of animal models of obesity
(15,16) and associated with visceral fat obesity in humans
(17,18). Consequently, it has been proposed that the
long-term effects of CB1 antagonism are resolved by
stimulation of energy expenditure and by peripheral ef-
fects related to adipose tissue, liver, skeletal muscle, and
pancreas physiology (19–21).
In the present work, we tested the effects of CB1
antagonism on the regulation of the liver and adipose
tissue lipid metabolism in a mouse model of diet-induced
obesity. We ﬁrst examined the global impact of CB1 antag-
onism on plasma parameters and liver steatosis, which were
primarily altered by long-term feeding of a high-sucrose
high-fat (HSHF) diet. Next, we examined whether CB1 inac-
tivation was associated with biochemical and molecular
alterations in the liver and adipose tissue (distinguishing
visceral and subcutaneous fat depots) that could account for
an improvement of liver lipid metabolism.
RESEARCH DESIGN AND METHODS
Ofﬁcial French regulations (no. 87848) for the use and care of laboratory
animals were followed throughout the experimental period. The experimental
protocol was approved by the local ethic committee for animal experimenta-
tion (no. BX0622). Four-week-old C57BL/6 male mice (Elevage Janvier, Le
Genest Saint Isle, France) were housed in individual plastic cages and adapted
to a standard diet (AO4; UAR, Epinay-sur-Orge, France) for 1 week. A series
of mice was maintained on the standard diet (CON group; n  5), while
another series was subjected to an HSHF diet containing casein 20%, corn
starch 13%, sucrose 29.3%, cellulose 5%, maltodextrin 2.2%, lard 20%, soya oil
2.5%, mineral 205B SAFE 7%, vitamin 200 SAFE 1% (ref. 235HF SAFE; Augy,
France). After 19 weeks, HSHF animals that were not both overweight and
hyperinsulinemic were excluded from the study. Selected mice were main-
tained on an HSHF diet and received orally either 10 mg  kg
1  day
1 of
SR141716 (HSHFSR series; n  14) or vehicle (HSHF series; n  10). The
CB1-speciﬁc antagonist SR141716 (Rimonabant) was supplied by sanoﬁ-
aventis (Paris, France). Animals had free access to fresh food and water
throughout the experimental period. Mice were food deprived 4 h before
anesthesia with ketamine/xylazine (7.5 mg  1m g
1  100 g body wt
1) and
tissue handling. Epididymal and inguinal fat were surgically removed as
representatives of visceral and subcutaneous fat, respectively (22). Tissue
samples were frozen in liquid nitrogen pending further analyses.
Serum and tissue parameters. Serum parameters were determined using
commercial kits (glucose RTU, TG PAP150, and cholesterol RTU from
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926 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgBioMe ´rieux [Marcy l’Etoile, France] for glucose, triglycerides, and cholesterol
assay, respectively; nonesteriﬁed fatty acid C from Wako Pure Chemical
Industries [Richmond, VA] for free fatty acid [FFA] assay; and mouse insulin
and adiponectine enzyme-linked immunosorbent assay kits from AbCys
[Paris, France]). Liver malonyl-CoA concentration was determined by high-
peformance liquid chromatography as previously described (23). Liver total
lipids were extracted according to the method of Folch et al. (24). After
mixing thoroughly, 1.0 ml of organic phase was transferred to a clean tube
containing 1 ml of 1% Triton X-100 in chloroform and dried using nitrogen. The
residue was resolubilized in 0.25 ml distilled water and used for the determi-
nation of triglycerides and cholesterol as in serum. For determination of
adiponectin content in adipose tissue, samples were homogenized in 10
volume of PBS. After centrifugation (10 min at 12,000g, 4°C), the supernatants
were carefully collected through the fat cake, diluted to 1/40,000 in PBS, and
used for adiponectine measurements as in serum.
Fatty acid oxidation and apolipoprotein A and B secretion. Freshly
removed livers from ﬁve HSHF and ﬁve HSHFSR mice were sliced using a
Brendel/Vitron slicer (Tucson, AZ), and thin slices were used to measure
[1-
14C] palmitic acid oxidation and apolipoprotein (apo) A and B secretion as
previously described (25).
[
3H]-cholesteryl ether-HDL uptake. Liver slices, prepared as described
above, were also intended for HDL uptake. First, an HDL fraction was isolated
from human plasma by sequential ﬂotation ultracentrifugations (26). HDL was
radiolabeled with [
3H]-cholesteryl ether (CE) combining [
3H]cholesteryl he-
dacyl ether with L-a-phosphatidylcholine and butylhydroxytoluene in a 500:1:6
molar ratio and sonicating to form liposomes. HDL-[
3H]CE was obtained by
addition of liposomes to the HDL fraction in presence of lipoprotein-free
plasma, as a source of CE transfer protein, after an overnight incubation at
37°C under light agitation. Labeled HDL was separated from remaining
liposomes by an other sequential ﬂotation ultracentrifugation and washed
twice in a solution of potassium bromide (density 1.21). Finally, HDL-[
3H]CE
was aliquoted and stored at 80°C until used. Measurement of the uptake was
carried out at 37°C by incubating two liver slices in 1 ml of William’s medium
E containing 40 g proteins (0.3 mCi of HDL-[
3H]CE) under slight agitation.
After 3 h, slices were removed from medium, washed three times, and
homogenized in 400 ml PBS with a mini-beadbeater (BioSpec Products,
Bartlesville, OK). The radioactivity recovered in the homogenate was ﬁnally
estimated, representing the amount of HDL uptaken by the liver cells.
Gene expression. Total mRNA from liver and adipose tissue were extracted
with Tri-Reagent (Euromedex, Souffelweyersheim, France) and reverse tran-
scripted using the Iscript cDNA kit (Bio-Rad, Marnes-La-Coquette, France).
Real-time PCR was performed as described previously (27) using a Bio-Rad
iCycler iQ. The sequences of forward and reverse primers used for the
ampliﬁcation are presented in the online supplemental Table 1 (available at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-1482/DC1).
Statistical analysis. Results are expressed as means  SE. Data were
analyzed statistically using the Kruskal-Wallis nonparametric test. Differences
were considered signiﬁcant at P  0.05.
RESULTS
Body and organ weights. Baseline body weights of the
three groups of mice were comparable. After 19 weeks,
body weights of HSHF animals were signiﬁcantly higher
than that of control mice (Fig. 1). From week 20 to 26, the
body weight of HSHFSR mice rapidly decreased to become
similar to that of CON mice at week 26 (Fig. 1). Consistent
with that, the masses of both epididymal and inguinal fat
pads differed in the order HSHF  HSHFSR  CON mice
(Table 1). Concomitantly, the liver weight was greater in
HSHF and less in HSHFSR than in CON mice (Table 1).
Serum and liver parameters. At the end of the experi-
ment, serum glucose concentration of HSHF mice was not
different from CON mice despite an increase in insulin
levels, indicating that the HSHF mice were in the early
stage of developing insulin resistance (Table 1). Likewise,
FFAs and total cholesterol levels were higher in HSHF
than in CON mice. Surprisingly, HSHF mice had 50% lower
plasma triglyceride levels than CON mice, suggesting an
increase in triglyceride clearance by the liver and adipose
tissue. In parallel with fat mass expansion, serum adi-
ponectin levels were less in mice fed with the HSHF diet
than in control mice. Interestingly, insulin and adiponectin
levels in HSHFSR mice were not different from the
control group (Table 1). Serum FFA concentration was
less in HSHFSR than in HSHF mice, while glucose,
triglycerides, and cholesterol levels did not differ between
these groups. In the liver, administration of HSHF diet
induced a steatosis with a ﬁvefold increase in triglyceride
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FIG. 1. Evolution of body weight during the induction period of obesity and during the treatment with CB1 antagonist. C57BL/6J mice were fed
an HSHF diet (42.3% carbohydrates, 22.5% lipids) for 25 weeks receiving orally during the last 6 weeks either 10 mg  kg
1  day
1 of the
CB1-speciﬁc antagonist SR141716 (HSHFSR; n  14) or the vehicle (HSHF; n  10). In parallel, a series of mice was maintained on a control
diet (CON; n  5). Results are expressed as means  SE. Results of statistical analysis were indicated at weeks 20 and 26, values with different
superscript letters (a, b, c) are statistically different at P < 0.05.
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changed. The malonyl-CoA content, a potent inhibitor of
fatty acid -oxidation, was also markedly increased. Mean-
while, glycogen stores were less in HSHF than in CON
mice, reﬂecting a stimulation of glycogenolysis. Interest-
ingly, triglyceride and malonyl-CoA accumulations were
partially reversed and glycogen concentration further de-
creased by CB1 antagonism (Table 1).
Adiponectin content in visceral and subcutaneous
fat. To explore whether the variations of serum adiponec-
tin levels could correspond to a different production of the
adipokine by visceral and subcutaneous fats, we deter-
mined the adiponectin content in epididymal and inguinal
fat, respectively. The adiponectin content was less in both
fat depots of HSHF than CON mice with a more marked
effect in inguinal fat. Remarkably, after treatment with
CB1 antagonist, the adiponectin content signiﬁcantly in-
creased in inguinal fat only (Fig. 2).
Fatty acid oxidation and parameters related to li-
poprotein metabolism. The ability of SR141716 to par-
tially reverse HSHF-induced liver steatosis prompted us to
verify whether this effect was related to an increased
capacity of hepatocytes to -oxidize fatty acid or to
produce lipids and lipoproteins. Palmitic acid -oxidation
rates measured in liver explants did not differ between
HSHF and HSHFSR mice (Table 2). ApoB secretion was
less with HSHFSR than HSHF explants, while apoA
secretion did not differ between the two groups. This
TABLE 1
Effects of CB1 antagonism on body composition, serum, and liver
parameters
CON group HSHF group
HSHFSR
group
n 51 0 1 4
Organ weight
Liver (g) 1.38  0.03* 1.49  0.06† 1.21  0.03‡
Epididymal fat (g) 0.67  0.14* 2.04  0.16† 0.98  0.07‡
Inguinal fat (g) 0.31  0.06* 1.10  0.10† 0.41  0.03*
Serum
Glucose (mg/ml) 2.79  0.16 2.72  0.21 2.53  0.08
Insulin (ng/ml) 0.40  0.03* 0.59  0.07† 0.44  0.03*
Adiponectin
(g/ml) 63.05  3.24* 42.31  7.21† 59.82  3.95*
FFAs (mmol/l) 0.30  0.04* 0.54  0.06† 0.43  0.03‡
Triglycerides
(mg/ml) 0.74  0.06* 0.36  0.03† 0.31  0.02†
Total cholesterol
(mg/ml) 1.09  0.04* 2.05  0.07† 1.87  0.06†
Liver
Glycogen (mg/g) 66.7  8.1* 49.2  4.2† 37.4  3.0‡
Triglycerides
(mg/g) 24.4  4.5* 118.7  17.6† 46.4  4.9‡
Total cholesterol
(mg/g) 16.07  0.94 17.98  1.63 15.72  0.7
Malonyl CoA
(nmol/g) 1.67  0.29* 3.43  0.52† 2.41  0.18‡
Data are means  SE. Mice were fed an HSHF diet for 25 weeks,
receiving during the last 6 weeks either 10 mg  kg
1  day
1 of the
CB1-speciﬁc antagonist SR141716 (HSHFSR) or the vehicle (HSHF
diet). In parallel, a series of mice was maintained on a control diet
(CON group). Mice were food deprived 4 h before tissue handling.
*,†,‡Statistically different at P  0.05.
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FIG. 2. Effect of CB1 antagonism on adiponectin concentration in visceral (A) and subcutaneous (B) fat. Mice were fed an HSHF diet for 25 weeks
receiving during the last 6 weeks either 10 mg  kg
1  day
1 of the CB1-speciﬁc antagonist SR141716 (HSHFSR; n  14) or the vehicle (HSHF;
n  10). In parallel, a series of mice was maintained on a control diet (CON; n  5). Adiponectin concentration was measured in adipose tissue
homogenates prepared as described in RESEARCH DESIGN AND METHODS. Results are expressed as means  SE. Values with different superscript
letters (a, b, c) are statistically different at P < 0.05.
TABLE 2
Effects of CB1 antagonism on fatty acid oxidation and parame-
ters related to lipoprotein metabolism in liver explants
HSHF HSHFSR
Palmitic acid oxidation (nmol 
h
1  g protein
1) 23.0  13 22.0  2.4
ApoB secretion (g  h
1 
g protein
1) 155  17* 123  8†
ApoA secretion (g  h
1 
g protein
1) 141  2 140  3
HDL-CE uptake (	
3H
-CE dpm 
h
1  g protein
1) 430  119* 1,075  139†
Data are means  SE. Thin liver slices (200 m) were obtained
from mice fed an HSHF diet and treated either with 10 mg  kg
1 
day
1 of SR141716 (HSHFSR; n  5) or vehicle (HSHF; n  5). For
fatty acid oxidation and apo secretion, slices were incubated at 37°C
in oxygenated William’s medium E supplemented with l-carnitine
(0.5 mmol/l) in the presence of 0.2 mmol/l of 	1-
14C
 palmitic acid
(55.5 GBq/mol) complexed to albumin (fatty acid/BSA molar ratio
2.5/1). After4ho fincubation, slices were rinsed with cold PBS and
immediately submitted to lipid extraction for counting of labelled
CO2 and acid-soluble products, while the incubation medium was
used for determination of apoB and apoA secreted. Measurement of
HDL uptake was carried out at 37°C by incubating liver slices with
	
3H
-CE-HDL under slight agitation for 3 h. Then, slices were washed
and homogenized in PBS. Radioactivity recovered in the homogenate
represented the amount of HDL uptaken by the liver cells. *,†Statis-
tically different at P  0.05.
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CB1 affected HDL-CE uptake. The recovery of HDL-CE
was greater in the liver explants from HSHFSR than
HSHF mice, suggesting interesting metabolic adaptations
that could affect lipid and lipoprotein metabolism (Table 2).
Gene expression in liver and adipose tissue
Liver. We ﬁrst tested the impact of the diet and of the
treatment with SR141716 on CB1 gene expression as an
indicator of ECS activity (Fig. 3). CB1 mRNA was the
greatest in HSHF mice and less in HSHFSR than in CON
mice, reﬂecting a stimulation of ECS in our mice model of
obesity and an effective inhibition of this pathway after
CB1 antagonist treatment. Then, mRNA levels of phos-
phoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6P) were measured as an indicator of liver
insulin resistance. The inverse relationship existing be-
tween insulin levels and expression levels of this two
enzymes suggested that insulin still had the ability to
control their transcription. In line with a possible impact
of CB1 antagonism on lipoprotein and cholesterol metab-
olism, we measured the mRNA expression of hepatic
lipase and scavenger receptor class B type I (SR-BI) in the
liver. The expression levels of these two genes were the
lowest in HSHF mice and did not differ from CON in
HSHFSR mice.
Besides, mRNA levels of the lipogenic enzymes acetyl-
CoA carboxylase (ACC) 1 and 2, and fatty acid synthase
(FAS) were all markedly less in HSHF than in CON mice.
Interestingly, the expression of both ACC isoforms was
higher in the liver of HSHFSR than HSHF mice, while
antagonism of CB1 had no effect on FAS expression. The
expression of stearoyl-CoA desaturase (SCD)-1, which
converts saturated fatty acids into monounsaturated fatty
acids, was higher in HSHF and less in HSHFSR than in
CON mice, suggesting that the inhibition of ECS could
have limited the high production of monounsaturated fatty
acids primarily induced by HSHF feeding. Besides, neither
the diet nor the treatment modiﬁed the transcript levels of
carnitine palmitoyltransferase (CPT)-I, the rate-limiting
enzyme of long-chain fatty acid -oxidation.
Adipose tissue. CB1 expression was also induced in both
visceral and subcutaneous adipose tissue of HSHF com-
pared with CON mice (Fig. 4A and B). In obese mice,
SR141716 treatment was efﬁcient in reducing CB1 expres-
sion in the two tissues. The expression of tumor necrosis
factor (TNF)-, an inﬂammatory cytokine associated with
insulin resistance, was higher in both visceral and subcu-
taneous fat of HSHF than CON mice. It is noteworthy that
the TNF- induction was dramatically higher in visceral
than in subcutaneous fat (24-fold vs. 4.8-fold, respec-
tively). Likewise, in HSHFSR mice, TNF- mRNA levels
were not different from CON mice in subcutaneous fat and
were only half that of CON mice in visceral fat. In addition,
compared with CON feeding, HSHF feeding gave rise to a
fourfold increase in the expression of the 
2 isoform of the
peroxisome proliferator–activated receptor (PPAR) 
2i n
visceral fat, while this induction was only twofold in
HSHFSR mice (Fig. 4A). In subcutaneous adipocytes,
PPAR
2 expression was surprisingly the highest in
HSHFSR mice, while the two other groups did not differ
each other (Fig. 4B). Concomitantly, the expression of
genes related to uptake (fatty acid translocase [FAT]/
CD36), lipolysis (hormone-sensitive lipase [HSL]), -oxi-
dation (CPT-I), and lipogenesis (FAS and ACC1) was
strongly higher in visceral fat of HSHF than CON mice
(Fig. 4A). Conversely, in subcutaneous deposits of HSHF
mice, the expression of these genes was either less than
CON mice (FAS and ACC1) or unchanged (FAT/CD36,
HSL, and CPT-I), suggesting different sensitivity and func-
tion of subcutaneous versus visceral adipocytes in condi-
tions of insulin resistance (Fig. 4B). Interestingly, in
visceral fat, all genes that were upregulated by HSHF
feeding were signiﬁcantly downregulated after treatment
with CB1 antagonist except FAT/CD36 (Fig. 4A).
DISCUSSION
In this study, the effects of CB1 antagonism were tested on
mice previously exposed to a long-term HSHF diet (19
weeks) with a lipid content and fatty acid composition
nearly similar to the human Western diet. Administration
of HSHF diet–induced obesity, liver fat accumulation and
peripheral insulin resistance as indicated by the elevation
of plasma insulin and FFA levels. A signiﬁcant number of
experimental reports describe beneﬁcial effects of CB1
antagonism on insulin resistance and fatty liver in mice
and humans, and these data strongly indicate that the ECS
has a major role in the regulation of lipid metabolism not
only at the central but also at the peripheral level (rev. in
28). From our mouse model of obesity, we provided
further evidence that CB1 blockade causes peripheral
metabolic and molecular changes in liver and adipose
tissue associated with the reversion of fatty liver. We
particularly showed that the lipid metabolism of visceral
and subcutaneous adipocytes was differently regulated in
response to diet-induced obesity and to CB1 antagonism.
Effects of CB1 antagonism on liver lipid metabolism.
Our ﬁndings clearly indicate that the strong upregulation
of liver CB1 primarily induced by an HSHF diet is fully
reversed by the treatment with SR141716, suggesting that
the metabolic improvements observed could be mediated
by the blockade of these receptors. This concept is sup-
ported by other studies using CB1
/ mice, demonstrating
that ECS overactivity occurs in the liver of animals fed a
high-fat diet and that hepatic CB1 are required for the
development of diet induced steatosis (14,29). In line with
this, the normalization of liver parameters related to
carbohydrate and lipid metabolism such as PEPCK, G6P,
ACC, and SCD-1 mRNA levels after treatment with CB1
antagonist strongly suggests that these adaptations corre-
spond to a normalization of liver insulin responsiveness as
evoked in muscles of rimonabant-treated ob/ob mice (21).
The activation of hepatic CB1 receptors has been recently
associated with an increase in de novo lipogenesis, sug-
gesting that this metabolic pathway participates to steato-
sis development in conditions of ECS overactivity (30).
Unlike this ﬁnding, we observed no stimulation of the liver
expression of ACC and FAS in HSHF animals, which were
quite hyperinsulinemic. In the works of Osei-Hyiaman et
al. (30), the stimulation of ECS consisted of an acute
injection of CB1 agonist to control animals, while in our
study, ECS activation was induced for a much longer
period using an HSHF diet. Since the diet contained high
proportions of saturated fatty acids, it can be hypothesized
that the provision of a diet rich in preformed saturated
fatty acids led to the reduced expression of mRNA for
lipogenic genes. The inhibitory effect of palmitoyl-CoA on
ACC demonstrated by Ogiwara et al. (31) supports this
concept. The induction of the SCD-1 gene and the increase
in monounsaturated fatty acid content in the liver of HSHF
mice (data not shown) indicate that saturated fatty acid
delivery to the liver was increased. Indeed, in HSHF mice,
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delivery of FFAs to the liver rather to an increase in de
novo lipogenesis. Aside from direct effects on the liver,
steatosis might have also been reduced indirectly by the
limitation of the inﬂux of fatty acids originating from
adipose tissue. The gene expression proﬁle of visceral
adipose tissue is consistent with an hyperactivation of
lipid metabolism as suggested by the strong upregulation
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release of fatty acids. Altogether, these data suggest that
the reversion of liver steatosis induced by the treatment
with CB1 antagonist was associated with an improvement
of adipose tissue metabolism.
In line with an improvement of cardiovascular risk in
type 2 diabetic patients treated with rimonabant (11,32),
our ﬁndings support the possibility that CB1 antagonism is
associated with an alteration of liver HDL catabolism.
Previous studies (33) showed that overexpression of SR-BI
in the liver, while reducing plasma HDL cholesterol levels,
reduced atherosclerosis in mice, suggesting that hepatic
SR-BI overexpression may promote reverse cholesterol
transport. Accordingly, the increase in SR-BI and hepatic
lipase expression induced by CB1 antagonism may be
associated with a modiﬁcation of HDL size and kinetics
(34) and thereby explain the increase in HDL-CE uptake
observed in our model of liver slices. Additional studies
are currently under investigation to clearly identify the
direct effects of CB1 antagonism on liver lipid metabolism.
Effects of CB1 antagonism on visceral fat. Recently,
evidence has accumulated from animal and human studies
(17,35–37) that obesity is also associated with overactiva-
tion of ECS in visceral fat. Concordant ﬁndings from this
study and from literature support the view that CB1
blockade exerts speciﬁc effects on visceral fat metabolism
that could be associated with the reduction of liver triglyc-
eride content. Hence, the coordinated upregulation of
genes acting at different levels of the lipogenic pathway
and that of the nuclear activator PPAR
 strongly sug-
gested that an HSHF diet favored triglyceride synthesis
and thereby formation of enlarged visceral fat deposits.
Adipocyte hypertrophy in obesity is consecutive to a
deﬁcit in adipogenesis (38), and the limitation of fat stores
would promote ectopic lipid deposition in liver and skel-
etal muscle, leading to decreased insulin action in these
tissues (39). Remarkably, the fact that CB1 antagonism
totally or partially normalized the expression levels of
lipogenic genes in adipocytes may limit the accumulation
of intracellular lipid droplets and give rise to smaller cells
and reduction of visceral fat mass as also suggested in
(40). The decrease in HSL expression consecutive to CB1
antagonism is of particular importance since excessive
HSL-dependent fat lipolysis leads to an increased release
of FFAs into the circulation, which in turn has deleterious
effects on insulin sensitivity (41).
It has been suggested recently that obesity-induced
inﬂammation of adipose tissue may directly activate ECS
(42). This could result in a protective response against
inﬂammation as described in colon (43). From our re-
search, it appears that ECS activation induced by an HSHF
diet is also associated with an increase in TNF- in
adipose tissue. This interaction between inﬂammation and
ECS needs to be further explored to determine whether
inﬂammation causes ECS activation or vice versa. How-
ever, the concentration-dependent stimulation of lipolysis
by TNF- demonstrated in rodent and human fat cells is
considered to be an important pathogenetic factor in the
development of insulin resistance and type 2 diabetes (44).
Therefore, it is reasonable to suggest that the reduction of
TNF- expression in visceral adipose tissue of HSHF mice
treated with CB1 antagonist is linked to the normalization
of adipocyte metabolism and to underlying effects on lipid
and carbohydrate metabolism.
Effects of an HSHF diet and CB1 antagonism in
subcutaneous versus visceral fat. This study also pro-
vides new information regarding the impact of HSHF diet
and subsequent CB1 antagonism on the regulation of lipid
metabolism in subcutaneous compared with visceral adi-
pose tissue. Taken together, our ﬁndings give molecular
evidence that 1) an HSHF diet causes deleterious effects in
visceral adipose tissue that were not observed in subcuta-
neous fat and 2) CB1 blockade is able to reverse the
molecular changes primarily induced by an HSHF diet in
visceral adipose tissue and to exert speciﬁc effects on
subcutaneous adipocytes. These discrepancies in gene
regulation between visceral and subcutaneous adipocytes
in response to high-fat diet and CB1 antagonism are
consistent with a different degree of ECS activation in
these tissues. This consideration is supported by several
recent ﬁndings (36,37,45,46) indicating differences in en-
docannabinoid levels between epididymal and subcutane-
ous fat. In addition, the overexpression of PPAR
2, FAS,
and ACC gene in epididymal fat of obese mice is also in
favor of the activation of ECS in this tissue since it has
been reported that CB1 activation stimulates lipogenesis
by increasing PPAR
 and lipogenic enzyme expression in
adipocytes and liver (30,36,47). Collectively, data suggest
that ECS is more activated in epididymal than in subcuta-
neous fat in our mice model of obesity and it can be
predicted that antagonism of CB1 was more effective in
the tissue presenting elevated levels of endocannabinoids
(36,45).
Interestingly, an HSHF diet or CB1 antagonist treatment
induced nearly similar effects on the amounts of epididy-
mal and subcutaneous fat, suggesting that molecular and
metabolic differences observed are not solely related to
the modiﬁcation of the fat depot size. In contrast, the
induction of TNF- expression by an HSHF diet was far
less important in subcutaneous than in visceral fat, and the
treatment of obese mice with CB1 antagonist induced the
complete normalization of TNF- expression only in sub-
cutaneous fat, whereas inﬂammation remains high in
visceral adipocytes. Concomitantly, the normalization of
TNF- mRNA levels in subcutaneous fat is associated with
an increase in adiponectin content in this tissue. An
inverse relationship between circulating adiponectin and
TNF- has already been evoked (48), suggesting that
adipose tissue inﬂammation could alter adiponectin pro-
duction. The increased expression of PPAR
2 induced by
CB1 antagonism in subcutaneous fat may also correspond
to an activation of adipocyte differentiation (49) and
thereby of adiponectin secretion (50). In addition, our
ﬁndings regarding the adiponectin content in visceral and
subcutaneous fat suggest that the normalization of adi-
ponectin plasma levels induced by CB1 antagonism may
be exclusively associated with an increased production of
this adipokine by subcutaneous adipocytes.
In conclusion, this study indicates that treating obese
mice with a CB1 antagonist exerts beneﬁcial effects on
liver steatosis and various lipid parameters, providing
supportive evidence that the hyperactivity of ECS associ-
ated with obesity was adjusted by the antagonism of CB1.
This notion is further supported by data from an ongoing
study indicating that CB1 antagonism exerts no effects on
body weight, fat mass, and liver triglyceride content in
control mice (T.J., L.Dj., L.De., J.G., B.V., and P.D.; per-
sonal data). Our ﬁndings are also consistent with a contri-
bution of peripheral CB1 and suggest different degrees of
ECS activity in visceral and subcutaneous fat. In this way,
CB1 ANTAGONISM IN DIET-INDUCED OBESE MICE
932 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgthe improvement of visceral adipose tissue metabolism
appears to be a determining factor for the normalization of
plasma parameters and the reversion of liver steatosis.
Therefore, future studies should investigate the direct
effects of CB1 antagonism on the liver to precise the
respective implication of ECS and products secreted by
adipose tissue in the regulation of lipid metabolism.
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